Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Confidential contracting

Bayer symbol

Bayer presents positive results for Kerendia in late-stage heart failure study

Approximately 55% of the 6.7 million heart failure patients in the US have an LVEF of at least 40%

- PMLiVE

Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome

There are currently no therapies in the US specifically approved to treat the rare genetic disorder

- PMLiVE

Hear From Her: Extraordinary Women Who Are Redefining Healthcare Leadership

That’s a wrap for Season 2 of Medscape Education’s Award-Winning Podcast Series, Hear From Her: Women in Healthcare Leadership! (Not to worry, Season 3 is just around the corner.)  And...

Medscape Education

- PMLiVE

Leading the way on the path to patient centricity

Find out how Mednet is leading the way to a truly patient-centric future for Pharma

Mednet

- PMLiVE

Bringing Clinicians Together for Oncology Education at ESMO 2024

ESMO 2024 comes with the debut of 2 new, exciting symposia hosted by the MedscapeLIVE! team. The symposia build on nearly 30 years of Medscape’s experience and excellence in both...

Medscape Education

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination granted EC approval

Bladder cancer is the fifth most commonly diagnosed cancer in Europe, with more than 165,000 annual cases

- PMLiVE

Sanofi’s investigational BTK inhibitor tolebrutinib shows promise in phase 3 MS study

The neurological disorder affects approximately 2.9 million people worldwide

- PMLiVE

Alnylam shares positive phase 3 results for vutrisiran in ATTR with cardiomyopathy

The company said it will be proceeding with regulatory filings for the therapy later this year

Clipboard inside Cuttsy+Cuttsy branded shapes

Closing the loop: Why clinical trial results matter to participants

Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.

Cuttsy + Cuttsy

- PMLiVE

GSK’s RSV vaccine Arexvy approved by EC for use in adults aged 50 to 59 years

An estimated 20 million adults in this age population are at an increased risk of severe RSV outcomes

- PMLiVE

UK government launches £400m investment programme to support clinical research

Up to 18 clinical trial hubs will be created to accelerate the development of new drugs

- PMLiVE

Breast cancer drug found to help slow growth of rare childhood brain tumour

Researchers discovered that targeting the CDK6 protein could make tumour cells vulnerable to treatment

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links